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INTRODUCTION
The skin is the largest organ and protects against dangerous envi-
ronmental factors and water loss. Skin is composed of two main 
layers: the dermis and the epidermis. The dermis contains a vari-
able amount of fat, collagen, and elastic fibers that provide strength 
and flexibility to the skin. 
 Keloids are benign hyperproliferative growths of dermal fibro-
blasts characterized by the excessive deposition of extracellular 
matrix components, especially collagen, fibronectin, elastin, pro-
teoglycans, and growth factors such as transforming growth factor 
(TGF) β [1]. The mechanisms of keloid formation include altera-
tions in growth factors, collagen turnover, and tension alignment, 
as well as genetic and immunological contributions. Trauma, 
foreign-body reactions, infections, and endocrine dysfunctions 
have all been proposed as risk factors for the development of ke-
loids after surgery in genetically susceptible people [1,2]. Keloid 
disease affects both sexes equally [3,4] and can occur at every age 
but is more prevalent between the ages of 10 and 30 [5].
EVIDENCE OF A GENETIC BASIS 
FOR KELOID DISEASE
Evidence from ethnic groups, families, and twins
The incidence of keloids is different among populations that 
reflect different etiologic factors. The worldwide keloid disease 
prevalence varies according to ethnicity. Patients with darker 
skin, however, have a higher prevalence than those with lighter 
pigmentation [6]. It is the fifth most common skin disease in 
adult black patients in the United Kingdom [3] and the most 
common skin disease among ethnic Chinese patients in Asia 
[7]. In addition, many reports have been published on familial 
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keloid cases [5,8-11], reflecting the importance of genetic fac-
tors among these families. Finally, the high frequency of identical 
twins both developing keloids also strongly supports a role for 
genetics in keloid etiology [5,12].
 Both autosomal dominant with incomplete penetrance and 
variable expression modes [5,9,10] as well as autosomal recessive 
modes of inheritance [13] have been seen among families with 
keloid disease. Clinical and genetic heterogeneity with a variable 
clinical expressivity between families and within the affected 
members of same family has been noted [5,8-11]. While the 
autosomal dominant mode of inheritance with incomplete pen-
etrance is the most common reported model for keloid disease, 
it remains unclear whether keloid disease is a simple Mendelian 
or a complex oligogenic disorder. As reviewed more recently, it is 
well known that environmental factors can trigger the formation 
of keloids in genetically susceptibility individuals [14]. In addi-
tion, studies on people of different ethnicities have discovered 
non-overlapping associated genes and genomic regions. Taken 
together, these investigations indicate that a complex inheritance 
model with contributions from multiple genetic factors along 
with triggering environmental influences could be the best mod-
el for keloid disease. More specifically, it seems plausible that an 
autosomal gene may play a major role in combination with more 
moderate recessive gene effects. 
Evidence from Mendelian disorders with keloid symp-
toms
Several Mendelian disorders manifest keloids as part of their 
clinical features. Individuals with a connective-tissue disorder, 
for example, have a possibility of developing keloids as part of 
their disease. Almost all Mendelian syndromic forms of keloid 
disease such as lateral meningocele (OMIM #130720), Rubin-
stein-Taybi (OMIM #180849), Leigh necrotizing encephalomy-
elopathy (OMIM #161700), Ullrich congenital muscular dys-
trophy (UCMD; OMIM #254090), Ehlers-Danlos syndrome 
(OMIM #130050), and Goeminne TKCR syndrome (OMIM 
#314300) have shown a dominant mode of inheritance that is 
consistent with the mode of inheritance among families with 
non-syndromic keloid disease [5,9,10].
 Rubinstein-Taybi syndrome 1 (RSTS1) patients develop ke-
loids with high frequency. RSTS1 is caused by a contiguous gene 
deletion involving the CREBBP gene as well as other neighbor-
ing genes on the chromosome 16p13.3 (OMIM #180849). A 
questionnaire-based study of 61 adults with RSTS ranging in age 
from 18 to 67 years found that 57% of patients developed keloids 
[15]. In addition, 28 patients exhibited keloids in a series of 574 
examined individuals with RSTS [16]. The high incidence of ke-
loids as both a proliferative disorder and as neoplasms in RSTS 
patients is attributed to the function of CREBBP in cAMP-
regulated cell immortalization [17].
 Nadeau et al. [18] reported the medical history of 13 patients 
with UCMD, three of which also had keloids. UCMD is a hetero-
geneous disease mainly caused by mutations in collagen genes. 
Similarly, Ehlers–Danlos syndrome (EDS) is an autosomal dom-
inant connective-tissue disorder that manifests keloids as one of 
the clinical symptoms. EDS type IV is caused by a heterozygous 
mutation in the gene for type III collagen (COL3A1; 120180) 
on chromosome 2q31, close to the gene locus for UCMD syn-
drome. In addition, overlapping phenotypes have been observed 
between EDS and UCMD. Finally, Goeminne TKCR syndrome 
was first reported in a family with six affected members in whom 
two patients also developed multiple keloids [19].
 Therefore, familial aggregation, occurrence in identical twins, 
Mendelian modes of inheritance, expression studies, and the 
high prevalence of keloids among different ancestries all provide 
strong evidence in favor of genetic factors in keloid formation. 
GENETIC STUDIES OF KELOID 
DISEASE
Evidence from expression studies and gene interaction
There are 166 studies on PubMed with “gene expression in 
keloid” as a keyword. With the advent of microarray expression 
platforms, a long list of genes has been found to be either up-
regulated or down-regulated in keloid samples. Keloid disease is 
a complex condition in which multiple interactions between the 
susceptible genes and their products have been reported. Keloids 
are enriched in growth factors and extracellular matrix (ECM) 
molecules, and fibroblasts compose the majority of dermis cells 
responsible for the production and remodeling of extracellular 
matrix during wound healing. ECM molecules play an important 
role in skin structure; therefore, disruption of the ECM could be 
responsible for abnormal scar tissue formation [20]. 
 As shown in Fig. 1, collagens (type I and III), microﬁbrillar 
proteins (elastin, ﬁbrillin) and hyaluronic acid are three major 
structural elements of the ECM [20]. Of these, collagens act as 
a network throughout the dermis to maintain tissue integrity 
and microﬁbrillar proteins allow flexibility in the deeper dermis 
[20]. Extensive expression studies focusing on ECM proteins 
have been carried out. Most expression studies have been con-
ducted on keloid-derived cultured fibroblast cells in comparison 
with normal tissue. The influence of cell culture components, 
which are in direct interaction with fibroblast cells, on gene 
expression is unavoidable. Keloid tissue is characterized by the 
accumulation of extracellular matrix, especially collagen (Fig. 
1). In addition, keloid-derived fibroblast cells exhibit high ex-
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pression of TGF β1 and TGF β2 [21] and consequently over-
synthesis of collagen [22,23]. TGF β stimulates the synthesis of 
collagen and promotes wound healing via regulating the growth, 
differentiation, and proliferation of fibroblast cells [24]. TGF 
β3 stimulates collagen synthesis via TGF β1 [22] and TGF β2 
[23]. In addition, the TGF β pathway is involved in fibrosis as 
well as several other fibrotic disorders [14]. It has been shown 
that in the primary stages of fibrosis in keloid tissues, TGF β1 is 
expressed by neovascular endothelial cells, which consequently 
stimulates the expression of type I and VI collagens at a high level 
[25]. TGF β1 is a key factor in keloid development and regulates 
the expression of multiple downstream genes. Exogenous TGF 
β1 upregulates the expression of platelet derived growth factor 
(PDGF) α receptor in keloid-derived fibroblast cells but not in 
non-keloid-derived fibroblast cells [26]. It has also been shown 
that TGF β stimulates the expression of vascular endothelial 
growth factor (VEGF) in keloid fibroblasts as well [27].
 SMAD genes act downstream of TGF β in keloid develop-
ment. In keloid fibroblast cells, SMAD2 small interfering RNAs 
(siRNA) caused the downregulation of SMAD2 and SMAD3, 
resulting in a decrease in procollagen levels [28,29]. This in-
dicates that SMAD2 and SMAD3 play a critical role in TGF 
β-induced fibrosis in the formation of keloids. 
EVIDENCE FROM LINKAGE AND  
ASSOCIATION STUDIES
As mentioned above, familial aggregation studies shed light on 
the genetic risk factors that might be responsible for keloid forma-
tion. Several researchers have since attempted to map the suscep-
tible locus (or loci) of keloid disease in these families. 
 Genome-wide linkage studies on a Japanese and an African-
American family with keloid disease resulted in the detection 
of linkage intervals on chromosomal regions 2q23 and 7p11, 
respectively [9]. However, linkage to 7p11 was excluded from 
a large Chinese family with keloid disease [30], and linkage in-
tervals at 15q22.31-q23, 18q21.1, and 10q23.31 were found for 
this family [31,32]. The 18q21.1 region harbors the SMAD 2, 7, 
and 4 genes, which are involved in regulating of TGF β signaling 
pathway.
 Multiple case-control studies have been published on the asso-
ciations between keloid disease and keloid candidate genes [33-
40]. Despite strong evidence from expression studies, no study 
has yet found any association between TGF β family members 
and keloid disease in Caucasian populations [33-36]. However, 
TGF β1 plasma concentration was found to be associated with 
the -509 T>C variant of TGF β1 [41], conflicting with results 
observed in another study [34].
 In addition, downstream genes in the TGF β signaling path-
way, namely SMAD 3, 6, and 7, did not attain statistical signifi-
cance in a case-control study examining keloid disease in the 
Afro-Caribbean ethnicity [42].
 In contrast to TGF β family members, HLA genes have at-
tained statistical significance in several studies [37,39,43]. Of 
these, HLA-DRB1*15 appeared to be the most robust with rep-
lication in both Chinese and Caucasian ethnic groups [37,39], 
suggesting that, at least in these ethnic groups, HLA-DRB1*15 
might be associated with an increased risk of keloid disease. 
GENOME-WIDE STUDIES IN KELOID 
DISEASE
With the advent of high-throughput microarray genotyping tech-
nologies, researchers have used these methods to look through 
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Fig. 1. Extracellular matrix (ECM) in normal skin, and hypertrophic and keloid tissue
ECM components in normal skin compared with hypertrophic scars and keloid tissue. The numbers indicate relative expression. Six means very high 
expression and -4 indicates very low expression.
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the entire genome. However, there is still no genome-wide link-
age study using high-density single-nucleotide polymorphism 
(SNP) map arrays on families with keloid disease. Recently, 
however, in a genome-wide case-control association study on a 
Japanese population, four susceptibility loci for keloid disease 
were detected including 1q41, 3q22.3-23, and 15q21.3 [44]. A 
replication study confirmed the possible role of the NEDD4 gene 
in the 15q21.3 chromosomal region. It has since been shown that 
NEDD4 upregulates fibronectin and type 1 collagen and so plays 
a role in the accumulation of extracellular matrix [45]. In an-
other study, copy number variations in 6p21.32, 11q11, 17q12, 
8p23.1, 22q13.1, 19p13.1, and 2q14.3 were detected using an 
array-based comparative genomic hybridization [43]. Region 
6p21.32, which harbors HLA-DRB5, also showed a significant 
association in the validation study.
THE ROLE OF EPIGENETICS IN  
KELOID DISEASE
The role of epigenetics in the formation of malignancies is well 
known. As a keloid is a benign tumor, the possibility of epigenetic 
alterations in keloid tissue exists. Indeed, it was recently reported 
that keloid fibroblast cells have altered patterns of DNA methyla-
tion and histone acetylation [46]. Examining the methylation 
profile could give new insight into keloid treatment. However, 
additional study is needed to fully address the role of epigenetics 
in the etiology of keloid disease.
CONCLUDING REMARKS AND  
OUTLOOK
Keloid disease is a complex condition in which different ethnic 
groups show different susceptibilities to the development of 
the disease. The differences in prevalence between populations 
probably reflect the contributions of different genetic risk fac-
tors. In general, most genes in complex disorders have a moder-
ate effect; therefore, association studies, which are powerful 
methods for detecting genes with moderate effects, are excellent 
for examining these types of disorders. A range of statistical 
methods including single marker analysis, genotype analysis, 
haplotype analysis, relative risk analysis, and gene-gene and 
gene-environment interaction analyses are also needed to find 
candidate genes in keloid disease etiology. In addition, a lack of 
reproducibility among some populations might be the result of 
small sample size, population stratification, inappropriate statisti-
cal analysis methods, or real heterogeneity among populations. 
 A change in an amino acid alone may not be a sufficient 
criterion for predicting disease in complex traits such as keloid. 
Variants could also exert effects by disrupting or activating the 
function of splicing binding sites, or hypomorphic variants could 
exert their effects at the transcription level and interact with oth-
er risk factors. However, as no single mutation inside a gene has 
been detected so far, a multifactorial inheritance model would fit 
best. Therefore, the interaction between genes and environmen-
tal factors, as well as the possible role of coding and regulatory 
variants and epigenetics must be accounted for in future studies.
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